{"DataElement":{"publicId":"2646471","version":"1","preferredName":"Kaposi Sarcoma Related Orbit Edema Intervention Type","preferredDefinition":"the type of intervention for periorbital edema.","longName":"KS_R/T_O_ED_INTVN_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2644223","version":"1","preferredName":"Kaposi Sarcoma Related Orbit Edema Interventions","preferredDefinition":"information relating to an intervention (an action intended to alter the course of a pathologic process) for Kaposi Sarcoma (a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells) related periorbital (around the bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa) edema (pathological transudate within one or more tissues).","longName":"KS_R/T_ORB_ED_INTVN","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2640556","version":"1","preferredName":"Kaposi Sarcoma Related Orbit Edema","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).:Related; connected or associated.:The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa.  Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.:Pathological transudate within one or more tissues.(FMA)","longName":"C9087:C25648:C12347:C3002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Relationship","conceptCode":"C25648","definition":"A state of connectedness between people, objects, or events; to be associated or connected with something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Orbit","conceptCode":"C12347","definition":"The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Edema","conceptCode":"C3002","definition":"Accumulation of an excessive amount of fluid in cells or intercellular tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"310FD3FA-BF3C-5037-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-22","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-22","modifiedBy":"ONEDATA","dateModified":"2007-05-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2644207","version":"1","preferredName":"Interventions","preferredDefinition":"An action or ministration that produces an effect or that is intended to alter the course of a pathologic process.","longName":"C16197","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interventions","conceptCode":"C16197","definition":"An action or ministration that produces an effect or that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"313B492E-CF4D-3B0F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-24","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-24","modifiedBy":"ONEDATA","dateModified":"2007-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"313A9F94-E327-43CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2646472","version":"1","preferredName":"Kaposi Sarcoma Related Orbit Edema Intervention Type","preferredDefinition":"the type of intervention for periorbital edema.","longName":"KS_R/T_O_ED_INTVN_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Analgesics","valueDescription":"Analgesics","ValueMeaning":{"publicId":"2646474","version":"1","preferredName":"Analgesics","longName":"2646474","preferredDefinition":"Analgesics","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3205C84E-C2E5-600E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3205B3A4-0DBD-5E39-E044-0003BA3F9857","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"ONEDATA","dateModified":"2007-06-03","deletedIndicator":"No"},{"value":"Local therapy","valueDescription":"Local therapy","ValueMeaning":{"publicId":"2646473","version":"1","preferredName":"Local therapy","longName":"2646473","preferredDefinition":"Local therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32057CFE-BE8E-42B7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3205B3A4-0DCF-5E39-E044-0003BA3F9857","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"ONEDATA","dateModified":"2007-06-03","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3205B3A4-0DDB-5E39-E044-0003BA3F9857","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"ONEDATA","dateModified":"2007-06-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3205BE11-AC39-6012-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Interventions for Periorbital","type":"Preferred Question Text","description":"Interventions for Periorbital Edema","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3205B3A4-0D98-5E39-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-03","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}